Abstract
In sarcomas, the TP53 tumour suppressor pathway may be altered either by TP53 mutations or by amplification of MDM2, encoding a protein that inhibits TP53 and targets it for 26S-proteasome degradation. However, in the majority of the analysed clinical samples, neither of these types of aberrations are found, suggesting that additional mechanisms are involved. The present study shows that COPS3, located in 17p11 and encoding a component of the proteasome pathway, is more frequently amplified in osteosarcomas (OS) than is MDM2. We present detailed analysis of TP53 mutations and MDM2 and COPS3 expression levels in a set of 23 OS. Our results show that none of the tumours with COPS3 amplification had MDM2 amplification nor TP53 mutations, consistent with the hypothesis that one of the three aberrations is sufficient. The results suggest that inactivation of otherwise intact TP53 by aberrations in the proteasome pathway may contribute to the characteristic aneuploidy observed in OS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C and Dubiel W . (2001). EMBO J., 20, 1630–1639.
Bech-Otschir D, Seeger M and Dubiel W . (2002). J. Cell Sci., 115, 467–473.
Berner J-M, Forus A, Elkahloun A, Meltzer PS, Fodstad Ø and Myklebost O . (1996). Genes Chromosome Cancer, 17, 245–259.
Bridge JA, Nelson M, McComb E, McGuire MH, Rosenthal H, Vergara G, Maale GE, Spanier S and Neff JR . (1997). Cancer Genet. Cytogenet., 95, 74–87.
Cho Y, Gorina S, Jeffrey PD and Pavletich NP . (1994). Science, 267, 346–355.
El-Rifai W, Sarlomo-Rikala M, Knuutila S and Miettinen M . (1998). Am. J. Pathol., 153, 985–990.
Elsea SH, Mykytyn K, Ferrell K, Coulter KL, Das P, Dubiel W, Patel PI and Metherall JE . (1999). Am. J. Med. Genet., 87, 342–348.
Fletcher JA, Gebhardt MC and Kozakewich HP . (1994). Cancer Genet. Cytogenet., 77, 81–88.
Flørenes VA, Maelandsmo GM, Forus A, Andreassen Å, Myklebost O and Fodstad Ø . (1994). J. Natl. Cancer Inst., 86, 1297–1302.
Forus A, Flørenes VA, Maelandsmo GM, Meltzer PS, Fodstad Ø and Myklebost O . (1993). Cell Growth Differ., 4, 1065–1070.
Forus A, Olde Weghuis D, Smeets D, Fodstad Ø, Myklebost O and Geurts van Kessel A . (1995a). Genes Chromosome Cancer, 14, 15–21.
Forus A, Olde Weghuis D, Smeets D, Fodstad Ø, Myklebost O and Geurts van Kessel A . (1995b). Genes Chromosome Cancer, 14, 8–14.
Hansen DV, Hsu JY, Kaiser BK, Jackson PK and Eldridge AG . (2002). Oncogene, 21, 6209–6221.
Huang LS, Bock SC, Feinstein SI and Breslow JL . (1985). Proc. Natl. Acad. Sci. USA, 82, 6825–6829.
Hulsebos TJ, Bijleveld EH, Oskam NT, Westerveld A, Leenstra S, Hogendoorn PC and Bras J . (1997). Genes Chromosomes Cancer, 18, 279–285.
Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG and Healey JH . (1993). Cancer Res., 53, 16–18.
Link MP and Eilber F . (1993). Cancer: Principles & Practice of Oncology DeVita VT, Hellman S. and Rosenberg SA (eds). Lippincott: Philadelphia, pp. 1534–1551.
Lothe RA, Smith-Sørensen B, Hektoen M, Stenwig AE, Mandahl N, Sæter G and Mertens F . (2001). Genes Chromosome Cancer, 30, 202–206.
Mertens F, Mandahl N, Orndal C, Baldetorp B, Bauer HC, Rydholm A, Wiebe T, Willen H, Akerman M and Heim S et al. (1993). Int. J. Cancer, 55, 44–50.
Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y and Sasaki MS . (1995). Int. J. Cancer, 64, 342–346.
Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B . (1992). Nature, 358, 80–83.
Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, Terrier P, Ranchere-Vince D, Collin F, Myklebost O and Turc-Carel C . (1999). Genes Chromosomes Cancer, 24, 30–41.
Potocki L, Chen KS and Lupski JR . (1999). Genomics, 57, 180–182.
Sandberg AA and Bridge J . (1994). The cytogenetics of Bone and Soft Tissue Tumors. R.G. Landes Company: Austin.
Simons A, Schepens M, Jeuken J, Sprenger S, van de Zande G, Bjerkehagen B, Forus A, Weibolt V, Molenaar I, van den Berg E, Myklebost O, Bridge J, van Kessel AG and Suijkerbuijk R . (2000). Cancer Genet. Cytogenet., 118, 89–98.
Stock C, Kager L, Fink FM, Gadner H and Ambros PF . (2000). Genes Chromosomes Cancer, 28, 329–336.
Szymanska J, Tarkkanen M, Wiklund T, Virolainen M, Blomquist C, Asko-Seljavaara S, Tukiainen E, Elomaa I and Knuutila S . (1996). Genes Chromosom Cancer, 15, 89–94.
Tarkkanen M, Kaipainen A, Karaharju E, Bohling T, Szymanska J, Helio H, Kivioja A, Elomaa I and Knuutila S . (1993). Cancer Genet. Cytogenet., 68, 1–21.
Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J, Bohling T, Karaharju E, Hyytinen E, Knuutila S and Kallioniemi O-P . (1995). Cancer Res., 55, 1334–1338.
Weiss SW . (1994). Histological Typing of Soft Tissue Tumours. Springer-Verlag: Berlin.
Wolf M, Tarkkanen M, Hulsebos T, Larramendy F, Forus AOM, Aaltonen LA, Elomaa I and Knuutila S . (1999). Int. J. Cancer, 82, 329–333.
Acknowledgements
The work was supported by the Norwegian Cancer Society. We like to thank Anine B Dahlberg and Marianne Berg for excellent assistance to this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Henriksen, J., Aagesen, T., Maelandsmo, G. et al. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 22, 5358–5361 (2003). https://doi.org/10.1038/sj.onc.1206671
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206671
Keywords
This article is cited by
-
CNTNAP4 signaling regulates osteosarcoma disease progression
npj Precision Oncology (2023)
-
Osteosarcoma Overview
Rheumatology and Therapy (2017)
-
Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
Nature Communications (2017)
-
Integrated analysis of gene expression and genomic aberration data in osteosarcoma (OS)
Cancer Gene Therapy (2015)
-
Array-based comparative genomic hybridization for genomic-wide screening of DNA copy number alterations in aggressive bone tumors
Journal of Experimental & Clinical Cancer Research (2012)